Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

Claps M, Cerri S, Grisanti S, Lazzari B, Ferrari V, Roca E, Perotti P, Terzolo M, Sigala S, Berruti A

Open source

DOI
10.1007/s12020-017-1428-9
Published
2018 Jul
Container
Endocrine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12020-017-1428-9,
  title = {Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.},
  author = {Claps M and Cerri S and Grisanti S and Lazzari B and Ferrari V and Roca E and Perotti P and Terzolo M and Sigala S and Berruti A},
  year = {2018},
  journal = {Endocrine},
  doi = {10.1007/s12020-017-1428-9},
  url = {https://doi.org/10.1007/s12020-017-1428-9}
}

RIS

TY  - JOUR
TI  - Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.
AU  - Claps M
AU  - Cerri S
AU  - Grisanti S
AU  - Lazzari B
AU  - Ferrari V
AU  - Roca E
AU  - Perotti P
AU  - Terzolo M
AU  - Sigala S
AU  - Berruti A
PY  - 2018
JO  - Endocrine
DO  - 10.1007/s12020-017-1428-9
UR  - https://doi.org/10.1007/s12020-017-1428-9
ER  - 

APA

M, C., S, C., S, G., B, L., V, F., E, R., P, P., M, T., S, S., & A, B. (2018). Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.. Endocrine. https://doi.org/10.1007/s12020-017-1428-9

Source records